Rapamycin-Loaded mPEG-PLGA Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-alcoholic Fatty Liver Disease
出版年份 2020 全文链接
标题
Rapamycin-Loaded mPEG-PLGA Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-alcoholic Fatty Liver Disease
作者
关键词
-
出版物
Frontiers in Chemistry
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-05-28
DOI
10.3389/fchem.2020.00407
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Nutrient Regulation of Signaling & Transcription
- (2019) Gerald W. Hart JOURNAL OF BIOLOGICAL CHEMISTRY
- Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions
- (2019) Jianping Liu et al. Small
- A Binding Site Hotspot Map of the FKBP12–Rapamycin–FRB Ternary Complex by Photoaffinity Labeling and Mass Spectrometry-Based Proteomics
- (2019) Hope A. Flaxman et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease
- (2019) Wendi Teng et al. JOURNAL OF CONTROLLED RELEASE
- Lipotoxic Hepatocyte‐Derived Exosomal miR‐192‐5p Activates Macrophages via Rictor/Akt/FoxO1 Signaling in NAFLD
- (2019) Xiao‐Lin Liu et al. HEPATOLOGY
- Smart cancer nanomedicine
- (2019) Roy van der Meel et al. Nature Nanotechnology
- Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
- (2019) Gordon I. Smith et al. JOURNAL OF CLINICAL INVESTIGATION
- Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy
- (2018) Wan Zhou et al. CELL BIOLOGY INTERNATIONAL
- DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease
- (2018) Hanqing Chen et al. HEPATOLOGY
- Future therapy for non-alcoholic fatty liver disease
- (2018) Danny Issa et al. LIVER INTERNATIONAL
- Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target
- (2018) Dabin Liu et al. Science Translational Medicine
- Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- (2018) Zobair Younossi et al. HEPATOLOGY
- Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice
- (2018) Chad N. Brocker et al. JOURNAL OF LIPID RESEARCH
- Polyurethane Nanoparticle-Loaded Fenofibrate Exerts Inhibitory Effects on Nonalcoholic Fatty Liver Disease in Mice
- (2018) Yi-ni Cao et al. MOLECULAR PHARMACEUTICS
- Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis
- (2018) Xu-Yun Zhao et al. Nature Communications
- Lipid mediators of liver injury in nonalcoholic fatty liver disease
- (2018) Suthat Liangpunsakul et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- mTOR as a central hub of nutrient signalling and cell growth
- (2018) Joungmok Kim et al. NATURE CELL BIOLOGY
- Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
- (2018) Yao Yu et al. Advanced Science
- SREBP-regulated lipid metabolism: convergent physiology — divergent pathophysiology
- (2017) Hitoshi Shimano et al. Nature Reviews Endocrinology
- Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study
- (2017) Janet Bee et al. THORAX
- Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
- (2017) Ahad Eshraghian WORLD JOURNAL OF GASTROENTEROLOGY
- PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
- (2016) Jung Soo Suk et al. ADVANCED DRUG DELIVERY REVIEWS
- Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
- (2016) Yaron Rotman et al. GUT
- Encapsulation and Controlled Release of Rapamycin from Polycaprolactone Nanoparticles Prepared by Membrane Micromixing Combined with Antisolvent Precipitation
- (2016) Rahimah Othman et al. LANGMUIR
- Co-delivery of doxorubicin and quercetin via mPEG–PLGA copolymer assembly for synergistic anti-tumor efficacy and reducing cardio-toxicity
- (2016) Waseem Akhtar Qureshi et al. Science Bulletin
- Pathological Features of Fatty Liver Disease
- (2014) Matthew M. Yeh et al. GASTROENTEROLOGY
- Nanopharmaceuticals (part 1): products on the market
- (2014) Volkmar Weissig et al. International Journal of Nanomedicine
- Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease
- (2013) Yuki Kawano et al. JOURNAL OF GASTROENTEROLOGY
- Epidemiology of alcoholic and nonalcoholic fatty liver disease in China
- (2013) Jian-Gao Fan JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice
- (2013) Chih-Wen Lin et al. JOURNAL OF HEPATOLOGY
- Rapamycin encapsulated in dual-responsive micelles for cancer therapy
- (2012) Yi-Chun Chen et al. BIOMATERIALS
- Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles
- (2011) Hai Wang et al. BIOMATERIALS
- Pathology of nonalcoholic fatty liver disease
- (2010) Elizabeth M. Brunt Nature Reviews Gastroenterology & Hepatology
- The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats
- (2007) Tatsuhiro Ishida et al. JOURNAL OF CONTROLLED RELEASE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started